ASCO GU »Today's Science, Tomorrow's Treatment«

Keep up with the latest updates from the 2023 ASCO Genitourinary (GU) Cancers Symposium as BestPractice Nordic brings you updates from leading oncologists who attended. Notable studies presented at the event include the IMvigor130 and the ongoing CAPItello-280 trial.

From February 16-18, the 2023 ASCO Genitourinary (GU) Cancers Symposium brought together global experts to explore innovative research, care methodologies, and new technologies for advancing progress in GU oncology. The Symposium's theme, »Today's Science, Tomorrow's Treatment,« emphasized the rapid pace and potential of therapeutic advancements in GU oncology. Throughout the event, sessions delved into new targets, concepts, and drug combinations for GU malignancies, such as metastatic castration-resistant prostate cancer. Additionally, the Symposium highlighted fresh clinical practice approaches for managing complex care issues across various malignancies while also discussing artificial intelligence and providing updates on guidelines and key studies in prostate, bladder, and kidney cancers. BestPractice Nordic followed the congress and met with leading oncologists virtually.

Aristotle Bamias, Professor of Medical Oncology at the University of Athens, Greece, presented at ASCO GU the IMvigor130 study. This phase III study is a final Overall Survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC). Aristotle Bamias explains that the benefit-risk ratio of atezolizumab vs chemotherapy support atezolizumab as first-line treatment for cisplatin-ineligible patients with PD-L1 IC2/3 mUC.

During the ACSO-GU symposium, the CAPItello-280 trial's design and study endpoints were presented. This ongoing trial aims to validate the results of the ProCAID study, which explored the safety and effects of adding capivasertib to docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer (CRPC). To learn more about this topic, you can listen to a MEDtalk with Simon Crabb, MD and Associate Professor in Medical Oncology at the Southampton Experimental Cancer Medicine Centre, University of Southampton, United Kingdom.

Scan the QR code with your phone's camera and find the MEDtalks with Aristotle Bamias and Simon Crabb on our ASCO GU congress page.